獅子山集團(01127.HK)2024年淨利增加16%至2.14億港元
格隆匯3月27日丨獅子山集團(01127.HK)公告,於2024年,集團營業額增長4%至26.69億港元。儘管全球插圖圖書市場表現充滿挑戰,公司的收益增長仍受旗下匯星印刷及Papercraft印刷製造經營業務的收益增長所帶動。擁有人應佔純利於2024年增加16%至2.14億港元。該增長主要是由於公司的印刷製造經營業務表現有所改善,以及公司在要約收購後增持Quarto股權後,Quarto的利潤貢獻有所改善。
於2024年,中國圖書市場依然疲弱,中國大陸銷售圖書總值收縮6%,其中不包括學術出版。由於本地市場環境充滿挑戰,更多中國本土印刷商爭奪海外圖書印刷訂單,產能過剩對行業的印刷利潤造成下行壓力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.